Search Results - "Pfaller, Michael A."

Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment by Pfaller, Michael A., MD

“…Abstract Antifungal resistance continues to grow and evolve and complicate patient management, despite the introduction of new antifungal agents. In vitro…”
Get full text

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program by Diekema, Daniel J, Hsueh, Po-Ren, Mendes, Rodrigo E, Pfaller, Michael A, Rolston, Kenneth V, Sader, Helio S, Jones, Ronald N

“…Bloodstream infection (BSI) organisms were consecutively collected from >200 medical centers in 45 nations between 1997 and 2016. Species identification and…”
Get full text

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 by Pfaller, Michael A, Diekema, Daniel J, Turnidge, John D, Castanheira, Mariana, Jones, Ronald N

“…Abstract Background The emergence of antifungal resistance threatens effective treatment of invasive fungal infection (IFI). Invasive candidiasis is the most…”
Get full text

Epidemiology of invasive mycoses in North America by Pfaller, Michael A, Diekema, Daniel J

“…The incidence of invasive mycoses is increasing, especially among patients who are immunocompromised or hospitalized with serious underlying diseases. Such…”
Get more information

Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008 by Pfaller, Michael A, Andes, David R, Diekema, Daniel J, Horn, David L, Reboli, Annette C, Rotstein, Coleman, Franks, Billy, Azie, Nkechi E

“…This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective…”
Get full text

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015 by Shortridge, Dee, Castanheira, Mariana, Pfaller, Michael A, Flamm, Robert K

“…The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 isolates collected from 32 U.S. hospitals in the…”
Get full text

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance by Pfaller, Michael A, Messer, Shawn A, Woosley, Leah N, Jones, Ronald N, Castanheira, Mariana

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination by Castanheira, Mariana, Deshpande, Lalitagauri M., Messer, Shawn A., Rhomberg, Paul R., Pfaller, Michael A.

“…•Antifungal resistance has been slowly increasing among certain yeast species.•Emergence of yeast species with intrinsic resistance to antifungals has been…”
Get full text

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program by Diekema, Daniel J, Pfaller, Michael A, Shortridge, Dee, Zervos, Marcos, Jones, Ronald N

“…Abstract Background Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant…”
Get full text

Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry by Horn, David L., Neofytos, Dionissios, Anaissie, Elias J., Fishman, Jay A., Steinbach, William J., Olyaei, Ali J., Marr, Kieren A., Pfaller, Michael A., Chang, Chi-Hsing, Webster, Karen M.

“…Background. Candidemia remains a major cause of morbidity and mortality in the health care setting, and the epidemiology of Candida infection is changing…”
Get full text

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species by Pfaller, Michael A, Messer, Shawn A, Rhomberg, Paul R, Borroto-Esoda, Katyna, Castanheira, Mariana

“…SCY-078 (formerly MK-3118) is a novel orally active inhibitor of fungal β-(1,3)-glucan synthase (GS). SCY-078 is a derivative of enfumafungin and is…”
Get full text

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program by Pfaller, Michael A, Huband, Michael D, Shortridge, Dee, Flamm, Robert K

“…Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016…”
Get full text

T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis by Pfaller, Michael A, Wolk, Donna M, Lowery, Thomas J

“…Candidemia and other forms of invasive candidiasis pose a significant diagnostic challenge. In order to provide the best treatment, it is important to…”
Get full text

Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 by PFALLER, Michael A, MOET, Gary J, MESSER, Shawn A, JONES, Ronald N, CASTANHEIRA, Mariana

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011 by Pfaller, Michael A, Huband, Michael D, Rhomberg, Paul R, Flamm, Robert K

“…Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections…”
Get full text

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009) by Pfaller, Michael A, Messer, Shawn A, Moet, Gary J, Jones, Ronald N, Castanheira, Mariana

“…Abstract Minimum inhibitory concentration (MIC) data from the SENTRY Antimicrobial Surveillance Program generated by reference methods were analysed to compare…”
Get full text

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) by Pfaller, Michael A, Moet, Gary J, Messer, Shawn A, Jones, Ronald N, Castanheira, Mariana

“…Antifungal testing results from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) were analyzed for regional variations of invasive Candida species…”
Get full text

Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene by Lockhart, Shawn R, Frade, João P, Etienne, Kizee A, Pfaller, Michael A, Diekema, Daniel J, Balajee, S. Arunmozhi

“…We surveyed 497 isolates of Aspergillus fumigatus collected from 2008 to 2009 as part of the ARTEMIS global surveillance study for elevated MIC values to…”
Get full text

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program by Pfaller, Michael A, Messer, Shawn A, Rhomberg, Paul R, Castanheira, Mariana

“…The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical…”
Get full text

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds by Pfaller, Michael A, Messer, Shawn A, Rhomberg, Paul R, Jones, Ronald N, Castanheira, Mariana

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text